All In Biotech

Drug Trial Radar · NCT06953076

Ultrasound Transformation of Myomas During Relugolix-Estradiol-Norethisterone Treatment: The MySaturn Study

MyomaS Aspect Transformation at Ultrasound During Relugolix Estradiol Noretisterone Treatment: MySaturn Study

Last checked: Nov 20, 2026Latest source record: Aug 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

111

Planned (sponsor's estimate)

Start

May 2, 2025

Primary completion

May 2, 2026

Study completion May 2, 2027

Sponsor

Sponsor type
Academic, hospital or other
First posted
May 1, 2025

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Uterine fibroids are benign tumors originating from the uterine muscle, affecting up to 70% of women by their 50s. Risk factors include African descent, nulliparity, obesity, and diabetes. While many fibroids are asymptomatic, 25-50% of affected women experience symptoms like heavy menstrual bleeding, pelvic pain, and pressure-related issues. Accurate diagnosis and differentiation from rare malignant tumors (e.g., uterine sarcomas) remain challenging, particularly before surgery. Ultrasound is the first-line tool for evaluating fibroids, with specific features (e.g., shape, vascularity) helping distinguish benign from suspicious lesions. The MUSA guidelines standardize ultrasound terminology for myometrial assessments. Current treatment options vary based on symptoms and malignancy risk. Among pharmacologic options, the combination of relugolix, estradiol, and norethisterone has shown efficacy in reducing bleeding and pain in symptomatic fibroids, with a favorable safety profile. However, its impact on fibroid morphology and ultrasound appearance is not yet well understood.

Conditions

  • Uterine Bleeding
  • Uterine Leiomyomas
  • Uterine Hemorrhage
  • Uterine Neoplasms

Interventions

  • Relugolix/estradiol/norethisterone acetateDrug

    Oral therapy administered to patients with symptomatic uterine fibroids presenting with abnormal uterine bleeding

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To observe modifications in the volume of the myometrial lesion during treatment with relugolix/estradiol/norethisteroneTime frame: at baseline, and after 3 months, 6 months, and 12 months from treatment initiation
  2. To observe the ultrasound features of myometrial lesions during treatment with relugolix/estradiol/norethisteroneTime frame: at baseline, and after 3 months, 6 months, and 12 months from treatment initiation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC GINECOLOGIA ONCOLOGICA

    Roma, Italy · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.